Table of Contents: 2022 JANUARY–FEBRUARY No. 444
RxNorm January 2022 Release. NLM Tech Bull. 2022 Jan-Feb;(444):b1.
The RxNorm January monthly release became available for download on Monday, January 3, 2022 and contains three COVID-19 related medications: Evusheld, Paxlovid, and molnupiravir.
RXNORM DATA CHANGES
Added Evusheld, Paxlovid & molnupiravir COVID-19 Related Medications
The FDA recently issued Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld, Pfizer's Paxlovid, and Merck's molnupiravir, and they are included in the RxNorm January 2022 monthly releases.
Evusheld is a prophylactic medication for COVID-19 for certain adults and pediatric individuals and it contains the antibodies tixagevimab co-packaged with cilgavimab, which are administered together. Paxlovid and molnupiravir are oral pills that treat COVID-19 disease. Both can be used in adults. Paxlovid can also be used in certain children over 12 years of age.
Here are the new COVID-19 related concepts in RxNorm:
| RXCUI | TTY | RxNorm Name |
| 2587313 | BPCK | {1 (1.5 ML cilgavimab 100 MG/ML Injection) / 1 (1.5 ML tixagevimab 100 MG/ML Injection) } Pack [Evusheld 2 vial carton] |
| 2587312 | GPCK | {1 (1.5 ML cilgavimab 100 MG/ML Injection) / 1 (1.5 ML tixagevimab 100 MG/ML Injection) } Pack |
| 2587899 | BPCK | {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day] |
| 2587898 | GPCK | {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack |
| 2587906 | SCD | molnupiravir 200 MG Oral Capsule |
